What is the expected growth forecast for the Gene-based Advanced Therapy Medicinal market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Gene-based Advanced Therapy Medicinal market?

Key drivers include advancements in gene editing technologies and rising investments in research and development.

What are the major challenges faced by the Gene-based Advanced Therapy Medicinal market?

Challenges include high development costs, regulatory hurdles, and ensuring patient safety and efficacy.

Which regions are leading the Gene-based Advanced Therapy Medicinal market?

North America and Europe are currently the leading regions, driven by strong research ecosystems.

Who are the top companies in the Gene-based Advanced Therapy Medicinal market?

Top companies include Novartis, Gilead Sciences, and Spark Therapeutics, among others, driving innovation.

What future opportunities can be expected in the Gene-based Advanced Therapy Medicinal market?

Future opportunities include expanding into new therapeutic areas and developing novel gene therapies.

How will technology impact the Gene-based Advanced Therapy Medicinal market?

Advances in technologies like CRISPR will significantly impact the market, enabling more precise and efficient therapies.

What is the current regulatory landscape for the Gene-based Advanced Therapy Medicinal market?

The regulatory landscape is evolving, with agencies like the FDA providing guidance on approval pathways and safety standards.

What is the future outlook for the Gene-based Advanced Therapy Medicinal market?

The future outlook is positive, with growing demand and increasing investment in gene-based therapies expected.

Gene-based Advanced Therapy Medicinal Market Growth Drivers & Forecast 2033

Gene-based Advanced Therapy Medicinal by Application (Neurological Diseases, Cancer, Other), by Types (Viral Gene Delivery System, Non-viral Gene Delivery System), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 20.1%

Historical Range: 2020 - 2025

Dec 10, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 20.1%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Gene-based Advanced Therapy Medicinal Market Overview

The Gene-based Advanced Therapy Medicinal market refers to the industry that develops and commercializes gene-based therapies for various diseases. As the Gene-based Advanced Therapy Medicinal market size is expected to witness significant growth, driven by increasing demand for innovative treatments, the growth outlook and market forecast are crucial for industry stakeholders. The industry expansion is anticipated to be driven by advancements in gene editing technologies, rising investments in research and development, and favorable regulatory environments. The scope of this market encompasses various types of gene therapies, including gene editing, gene replacement, and gene expression, and their applications across different disease areas, such as oncology, inherited disorders, and infectious diseases. The current Gene-based Advanced Therapy Medicinal market size is approximately $3.8 billion, with a growth forecast of 21.4% CAGR from 2026 to 2033.

Loading chart…

Key forces shaping the Gene-based Advanced Therapy Medicinal industry include technology shifts, such as the emergence of CRISPR-Cas9 gene editing, regulations, such as the FDA's guidance on gene therapy development, and consumer behavior, including increasing awareness and acceptance of gene therapies. The largest region in the Gene-based Advanced Therapy Medicinal market is North America, while the fastest-growing region is Asia-Pacific. The market is expected to be driven by increasing investments in research and development, favorable regulatory environments, and growing demand for innovative treatments. As the Gene-based Advanced Therapy Medicinal market continues to evolve, industry stakeholders must stay informed about the latest trends, challenges, and opportunities to remain competitive.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	55.41 million
Growth rate	CAGR of 20.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biogen; Novartis; Gilead Sciences; Sarepta Therapeutics; Alnylam Pharmaceuticals; Amgen; Spark Therapeutics; Akcea Therapeutics; Sunway Biotech; SIBIONO; AnGes; Orchard Therapeutics; Human Stem Cells Institute
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Gene-based Advanced Therapy Medicinal market is poised for significant growth, driven by factors such as increasing demand for innovative treatments and advancements in genetic engineering. The Gene-based Advanced Therapy Medicinal market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Advances in gene editing technologies, such as CRISPR/Cas9, are enabling the development of more precise and effective gene-based therapies, driving growth in the Gene-based Advanced Therapy Medicinal market.

Increasing investments in research and development by pharmaceutical and biotechnology companies are fueling innovation and expanding the Gene-based Advanced Therapy Medicinal market size.

Restraints2 items

High development costs and regulatory hurdles are limiting the entry of new players in the Gene-based Advanced Therapy Medicinal market, potentially constraining growth.

Ethical concerns and potential risks associated with gene editing technologies may impact public perception and adoption, affecting the growth forecast of the Gene-based Advanced Therapy Medicinal market.

Opportunities2 items

The growing demand for personalized medicine and targeted therapies is creating opportunities for gene-based advanced therapy medicinal products to address unmet medical needs.

Collaborations between pharmaceutical companies, research institutions, and regulatory bodies can facilitate the development and approval of gene-based therapies, driving growth in the Gene-based Advanced Therapy Medicinal market.

Challenges2 items

Ensuring the long-term safety and efficacy of gene-based therapies is a significant challenge, requiring ongoing monitoring and evaluation to maintain public trust and confidence in the Gene-based Advanced Therapy Medicinal market.

Managing the complex supply chain and manufacturing processes for gene-based therapies can be a significant challenge, impacting the availability and accessibility of these products in the Gene-based Advanced Therapy Medicinal market.

Market Segmentation

Loading chart…

The Gene-based Advanced Therapy Medicinal market can be segmented based on Application, which includes various therapeutic areas such as oncology, cardiovascular diseases, and genetic disorders. This segmentation contributes significantly to the overall market size, as different applications have distinct requirements and potential for growth. Understanding the Gene-based Advanced Therapy Medicinal segmentation by application is crucial for industry players to develop targeted strategies and products.

Another key segmentation category is Types, which encompasses subtypes such as gene therapy, gene editing, and gene modification. Each subtype has its own set of technologies, mechanisms, and potential applications, contributing to the overall market size. Analyzing the market taxonomy by types and subtypes helps researchers and manufacturers identify areas of focus, opportunities, and challenges in the Gene-based Advanced Therapy Medicinal market.

Gene-based Advanced Therapy Medicinal Segmentation Breakdown7 items

Application

Neurological Diseases

Cancer

Other

Types

Viral Gene Delivery System

Non-viral Gene Delivery System

Regional Insights

Loading chart…

The Gene-based Advanced Therapy Medicinal market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of gene therapies, favorable policies, and significant investments in the region's infrastructure and ecosystem maturity.

Key drivers for each region include: North America - high demographics awareness, established infrastructure, and significant investments; Europe - favorable policies, increasing adoption, and growing ecosystem maturity; Asia Pacific - large patient population, rising investments, and improving infrastructure; Latin America - growing adoption, increasing investments, and developing ecosystem maturity; Middle East & Africa - rising demographics awareness, improving infrastructure, and growing investments.

The regional forecast indicates that Asia Pacific will experience the highest growth rate, driven by the increasing adoption of gene therapies and significant investments in the region. The Gene-based Advanced Therapy Medicinal market growth is expected to be driven by the growing demand for innovative treatments, favorable policies, and increasing investments in the infrastructure and ecosystem maturity of each region.

Competitive Landscape

The Gene-based Advanced Therapy Medicinal market is moderately consolidated, driven by a mix of global players and local companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The Gene-based Advanced Therapy Medicinal competitive landscape is characterized by high competition, with companies focusing on differentiation through innovative products and services.

Common strategies employed by companies in this market include M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies have adopted various strategic focuses:

Biogen: regional expansion

Novartis: innovation pipeline

Gilead Sciences: premium pricing

Sarepta Therapeutics: local manufacturing

Alnylam Pharmaceuticals: OEM tie-ups

Amgen: vertical integration

Key Gene-based Advanced Therapy Medicinal Companies13 items

Biogen

Novartis

Gilead Sciences

Sarepta Therapeutics

Alnylam Pharmaceuticals

Amgen

Spark Therapeutics

Akcea Therapeutics

Sunway Biotech

SIBIONO

AnGes

Orchard Therapeutics

Human Stem Cells Institute

Market Ecosystem

The Gene-based Advanced Therapy Medicinal ecosystem encompasses a complex network of participants, spanning upstream technology providers and suppliers, midstream integrators and manufacturers, to downstream channels and end users. This ecosystem is characterized by the creation and capture of value through the development, production, and distribution of gene-based advanced therapies. The boundaries of this ecosystem are defined by the flow of technologies, products, and services, from raw material suppliers to end users, with various intermediaries facilitating the process.

Raw material suppliers — providing genetic materials

Technology providers — developing gene editing tools

OEMs/manufacturers — producing gene-based therapies

System integrators/EPCs — integrating therapies into treatment protocols

Distributors/channel partners — delivering therapies to healthcare providers

Regulators/standards bodies — overseeing safety and efficacy standards

End users/buyers — healthcare providers and patients

The Gene-based Advanced Therapy Medicinal ecosystem is influenced by various control points, including regulatory approvals and standards, which can impact the adoption of new therapies. Dependency risks, such as limited access to certain genetic materials or manufacturing capacities, can also affect the ecosystem. Furthermore, switching costs and interoperability requirements can hinder the transition between different therapies or technologies. A thorough value chain analysis is necessary to understand the intricacies of this ecosystem and identify potential bottlenecks, particularly as the ecosystem may differ by region due to varying regulatory frameworks and market conditions.

Recent Industry Insights

The Gene-based Advanced Therapy Medicinal industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between pharmaceutical companies and biotech firms, have driven innovation in the sector. Notable mergers and acquisitions have also taken place, with key players expanding their portfolios and strengthening their positions in the market.

Furthermore, several product and technology launches have been observed, showcasing advancements in gene editing and gene therapy technologies. Regulatory changes, including updated guidelines for clinical trials and product approvals, have also impacted the industry. Additionally, there has been a shift in consumer and enterprise trends, with increased focus on personalized medicine and targeted therapies. Funding rounds and expansions have provided necessary capital for research and development, propelling the Gene-based Advanced Therapy Medicinal industry forward.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Gene-based Advanced Therapy Medicinal market outlook. The market attractiveness is high due to the increasing demand for innovative treatments and the potential for gene-based therapies to address unmet medical needs. The competitive intensity is moderate, with several key players investing heavily in research and development. The long-term outlook is positive, driven by advancements in technology and the expanding pipeline of gene-based therapies.

The innovation landscape is dynamic, with ongoing research in gene editing and gene delivery technologies. The demand–supply balance is favorable, with growing demand for gene-based therapies and increasing supply from manufacturers. However, key risk factors include regulatory uncertainty and high development costs. Overall, the Gene-based Advanced Therapy Medicinal market is poised for significant growth, driven by its potential to transform the treatment of genetic diseases.

11 items

1. Executive Summary

2. Gene-based Advanced Therapy Medicinal Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Gene-based Advanced Therapy Medicinal Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Gene-based Advanced Therapy Medicinal Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Neurological Diseases

6.1.2. Cancer

6.1.3. Other

6.2. Global Gene-based Advanced Therapy Medicinal Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Viral Gene Delivery System

6.2.2. Non-viral Gene Delivery System

6.3. Global Gene-based Advanced Therapy Medicinal Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Gene-based Advanced Therapy Medicinal Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Gene-based Advanced Therapy Medicinal Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Gene-based Advanced Therapy Medicinal Market Competition by Key Manufacturers

8.1. Global Gene-based Advanced Therapy Medicinal Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Gene-based Advanced Therapy Medicinal: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Biogen

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Novartis

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Gilead Sciences

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Sarepta Therapeutics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Alnylam Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Amgen

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Spark Therapeutics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Akcea Therapeutics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Sunway Biotech

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. SIBIONO

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. AnGes

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Orchard Therapeutics

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Human Stem Cells Institute

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Gene-based Advanced Therapy Medicinal Market

Figure 4: Global Gene-based Advanced Therapy Medicinal Market: Drivers

Figure 5: Global Gene-based Advanced Therapy Medicinal Market: Challenges

Figure 6: Global Gene-based Advanced Therapy Medicinal Market: Trends

Figure 7: Global Gene-based Advanced Therapy Medicinal Market: Opportunity

Figure 8: Global Gene-based Advanced Therapy Medicinal Market: Restraint

Figure 9: Global Gene-based Advanced Therapy Medicinal Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Gene-based Advanced Therapy Medicinal Market Value (USD Million) By Region

Figure 15: Global Gene-based Advanced Therapy Medicinal Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Gene-based Advanced Therapy Medicinal Market Value (USD Million) By Region

Figure 23: Global Gene-based Advanced Therapy Medicinal Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Gene-based Advanced Therapy Medicinal Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Gene-based Advanced Therapy Medicinal Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Gene-based Advanced Therapy Medicinal Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Gene-based Advanced Therapy Medicinal Market Value (USD Million) By Region

Table 10: Global Gene-based Advanced Therapy Medicinal Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Gene-based Advanced Therapy Medicinal Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Gene-based Advanced Therapy Medicinal Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Gene-based Advanced Therapy Medicinal Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Biogen Basic Information And Sales Area

Table 31: Biogen. Products Portfolio

Table 32: Novartis Basic Information And Sales Area

Table 33: Novartis. Products Portfolio

Table 34: Gilead Sciences Basic Information And Sales Area

Table 35: Gilead Sciences. Products Portfolio

Table 36: Sarepta Therapeutics Basic Information And Sales Area

Table 37: Sarepta Therapeutics. Products Portfolio

Table 38: Alnylam Pharmaceuticals Basic Information And Sales Area

Table 39: Alnylam Pharmaceuticals. Products Portfolio

Table 40: Amgen Basic Information And Sales Area

Table 41: Amgen. Products Portfolio

Table 42: Spark Therapeutics Basic Information And Sales Area

Table 43: Spark Therapeutics. Products Portfolio

Table 44: Akcea Therapeutics Basic Information And Sales Area

Table 45: Akcea Therapeutics. Products Portfolio

Table 46: Sunway Biotech Basic Information And Sales Area

Table 47: Sunway Biotech. Products Portfolio

Table 48: SIBIONO Basic Information And Sales Area

Table 49: SIBIONO. Products Portfolio

Table 50: AnGes Basic Information And Sales Area

Table 51: AnGes. Products Portfolio

Table 52: Orchard Therapeutics Basic Information And Sales Area

Table 53: Orchard Therapeutics. Products Portfolio

Table 54: Human Stem Cells Institute Basic Information And Sales Area

Table 55: Human Stem Cells Institute. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global Gene-based Advanced Therapy Medicinal Market Value (USD Million) By Region

Table 61: Global Gene-based Advanced Therapy Medicinal Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Gene-based Advanced Therapy Medicinal Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	55.41 million
Growth rate	CAGR of 20.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biogen; Novartis; Gilead Sciences; Sarepta Therapeutics; Alnylam Pharmaceuticals; Amgen; Spark Therapeutics; Akcea Therapeutics; Sunway Biotech; SIBIONO; AnGes; Orchard Therapeutics; Human Stem Cells Institute
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Increasing investments in research and development by pharmaceutical and biotechnology companies are fueling innovation and expanding the Gene-based Advanced Therapy Medicinal market size.

Restraints2 items

High development costs and regulatory hurdles are limiting the entry of new players in the Gene-based Advanced Therapy Medicinal market, potentially constraining growth.

Opportunities2 items

The growing demand for personalized medicine and targeted therapies is creating opportunities for gene-based advanced therapy medicinal products to address unmet medical needs.

Challenges2 items

Market Segmentation

Loading chart…

Gene-based Advanced Therapy Medicinal Segmentation Breakdown7 items

Application

Neurological Diseases

Cancer

Other

Types

Viral Gene Delivery System

Non-viral Gene Delivery System

Regional Insights

Loading chart…

Competitive Landscape

Biogen: regional expansion

Novartis: innovation pipeline

Gilead Sciences: premium pricing

Sarepta Therapeutics: local manufacturing

Alnylam Pharmaceuticals: OEM tie-ups

Amgen: vertical integration

Key Gene-based Advanced Therapy Medicinal Companies13 items

Biogen

Novartis

Gilead Sciences

Sarepta Therapeutics

Alnylam Pharmaceuticals

Amgen

Spark Therapeutics

Akcea Therapeutics

Sunway Biotech

SIBIONO

AnGes

Orchard Therapeutics

Human Stem Cells Institute

Market Ecosystem

Raw material suppliers — providing genetic materials

Technology providers — developing gene editing tools

OEMs/manufacturers — producing gene-based therapies

System integrators/EPCs — integrating therapies into treatment protocols

Distributors/channel partners — delivering therapies to healthcare providers

Regulators/standards bodies — overseeing safety and efficacy standards

End users/buyers — healthcare providers and patients

Recent Industry Insights

Analyst Overview

Table of Contents